ClinicalTrials.Veeva

Menu

Translating ECHOS2 Into an mHealth Platform

The Washington University logo

The Washington University

Status

Completed

Conditions

Cardiac Toxicity
Pediatric Cancer
Childhood Cancer

Treatments

Behavioral: Computerized Intervention Authoring Software (CIAS)

Study type

Interventional

Funder types

Other

Identifiers

NCT05923242
202305110

Details and patient eligibility

About

Childhood cancer survivors are at an increased risk of cardiac toxicity due to prior anti-cancer therapy. However, adherence to cardiac screening in this population remains low. This study aims to assess the feasibility of an mHealth motivational interviewing platform called Computerized Authoring Intervention Software (CIAS) in childhood cancer survivors. Participants will be recruited from the Childhood Cancer Survivorship Study.

Enrollment

73 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • 18 years of age or older
  • Diagnosed with cancer at age 17 or younger
  • 2 or more years after completion of cancer therapy
  • Receipt of cardiotoxic therapy (Any dose of anthracycline or 15 Gy chest radiation involving cardiac structures)
  • No history of cardiomyopathy
  • Have not received an echocardiogram in the past 5 years

Trial design

Primary purpose

Supportive Care

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

73 participants in 1 patient group

Computerized Intervention Authoring Software (CIAS)
Experimental group
Description:
Participants will be provided with a link to begin the study following consent, and the link will direct the participants to a baseline survey. At the end of the survey, participants will be automatically redirected to Computerized Intervention Authoring Software (CIAS). Participants will be encouraged to complete 2 sessions in CIAS, approximately 1 week apart. After completing the second session, CIAS will automatically redirect the participants to a post-test survey. Approximately 30 days after completing the second session, participants will be invited to complete a 30 day follow-up survey.
Treatment:
Behavioral: Computerized Intervention Authoring Software (CIAS)

Trial contacts and locations

1

Loading...

Central trial contact

Julia Maki, PhD; Erika Waters, PhD, MPH

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems